据HORIZON研究数据，这项技术联合白内障手术治疗轻中度原发性开角型青光眼，效果显著，术后24个月，患者未用药眼压平均降低7.5±4.1mmHg， 77.2%患者眼压降幅≥20%，78%患者可完全停用降压药物，安全性获长期验证。 此次首例手术的成功，体现了山东第二医科大学附属医院眼科中心在青光眼诊疗领域的技术实力。随着这项微创技术的推广，更多患者将摆脱药物依赖与 传统手术风险，以更小创伤获得持久眼压控制。 近年来，微创青光眼手术(MIGS)因其切口小、恢复快、安全性高，成为青光眼治疗新趋势。2025年，三重降压MIGS技术正式登陆中国，为患者带来更微 创、长效的选择。近日，山东第二医科大学附属医院眼科中心王俊团队成功完成山东省首例三重引流机制青光眼引流器(Hydrus Microstent)植入术，标志 着山东青光眼治疗迈入新阶段！ 据悉，这名患者为36岁原发性开角型青光眼，术前长期使用三种降眼压药物，但眼压仍波动在24mmHg左右，且已出现视神经损害与眼部刺激症状。在经 过王俊团队评估后，为其施行三重引流机制青光眼引流器植入术。手术创伤小、痛苦轻，术后第一天眼压即降至17mmHg的理想水平，无并发症，恢复 ...

Financial Data and Key Metrics Changes - Total revenue for the first quarter of 2025 was $17,500,000, reflecting a 9% decrease compared to the same period in the prior year [19][21] - Surgical glaucoma revenue was $17,100,000, a decrease of 6% year-over-year, primarily due to a 10% decrease in account utilization [20][21] - Dry eye revenue was $400,000, down from $1,000,000 in the same period last year, attributed to fewer SmartLids sales following a price increase [21][16] - Gross margin for the first quarter was 86%, unchanged from the prior year [21] - Net loss for the quarter was $14,200,000, or $0.28 per share, compared to a net loss of $16,300,000, or $0.33 per share, in the prior year [22] Business Line Data and Key Metrics Changes - Surgical glaucoma segment showed a slight decline in sequential ordering accounts, with a 3% increase year-over-year despite new Medicare restrictions [20][10] - The dry eye segment's revenue reflects ongoing efforts in market access and new pricing strategies [16][21] Market Data and Key Metrics Changes - The MIGS market is experiencing changes due to new Medicare coverage restrictions, limiting the number of MIGS procedures performed during cataract surgery [9][10] - The company is actively engaging with surgeons to adapt to the new environment and optimize commercial strategies [10][31] Company Strategy and Development Direction - The company is focused on addressing unmet medical needs in glaucoma and dry eye markets through innovative interventional technologies [7][15] - Strategic initiatives include building commercial momentum in MIGS, establishing equitable reimbursement for tier care, and advancing the product pipeline [7][15] - Plans to expand manufacturing operations outside of China to mitigate tariff impacts are underway [8][25] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the continued demand for glaucoma treatments and the company's ability to adapt to the new MIGS environment [10][9] - The company reaffirmed its revenue guidance for 2025, expecting total revenue of approximately $70,000,000 to $75,000,000 [23][24] - Management highlighted the importance of ongoing conversations with payers regarding reimbursement for tier care procedures [45][46] Other Important Information - The company has not yet received any monetary damages from a patent infringement case against Alcon, awaiting final rulings [22] - Adjusted operating expenses for the first quarter were $24,700,000, a decrease of 7% compared to the prior year [22][26] Q&A Session Summary Question: Can you discuss trends in surgical glaucoma and share dynamics? - Management noted a decline in actual utilization but emphasized the continued growth in patient encounters and the effectiveness of the Omni product [30][31] Question: Are there efforts to reverse the stacking component of the LCDs? - Management acknowledged multiple efforts to collect clinical data supporting the need for multiple MIGS procedures [36] Question: What are the reimbursement dynamics for Omni versus competitive MIGS devices? - The reimbursement dynamics remain largely unchanged, with most procedures historically performed as single MIGS [43] Question: Any updates on tier care reimbursement? - No coverage determinations have been made yet, but management is optimistic about future decisions [45][46] Question: Can you provide insights on the Scion product? - Scion is a complementary product with modest revenue contribution, primarily serving surgeons looking for simpler procedures [49][50] Question: What is the outlook for device intensive qualification? - Management expressed strong conviction that the device should qualify for device intensive but refrained from speculation [58] Question: How is the company addressing competitive launches? - Management remains confident in Omni's market position and is actively monitoring competitive dynamics [88]